Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for polypoidal choroidal vasculopathy
ISRCTN69073386Phase 4Completed
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, open-label, single-arm trial of faricimab in polypoidal choroidal vasculopathy (PCV), sponsored by Roche. Primary endpoint: Best-corrected visual acuity at week 48. Started Nov 2022; status: completed.
02
Drugs
faricimab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on ISRCTN69073386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN69073386.